TTFactor signs a Research Agreement with OncoMed Pharmaceuticals Inc. for Advancing Novel Cancer Therapies through IEO Scientific Expertise

Milan, December 9, 2011

TTFactor srl (the technology transfer company of IFOM and IEO) today announced a research collaboration with OncoMed Pharmaceuticals Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, to test OncoMed’s clinical candidates in a new generation of tumor models developed at the “Molecular Medicine for Care Program” of IEO, headed by Prof. Pier Paolo Di Fiore.

Click to download the full-text pdf Press_Release_ENG.pdf